Balanced news tone
News Sentiment
MOLN sentiment intelligence
Molecular Partners AG ADR news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
News tone and price action are not far from neutral.
79/100 classification confidence.
directly relevant articles
high-authority source matches
+1.1% over one week, -2.1% over four weeks, trend inactive, and near fair-value range.
Molecular Partners Doses First Patients in Phase 2 Study of Biliary Tract Cancer Therapy
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
Corporate Revenue Breakdown
This article from TradingKey provides a revenue breakdown for Molecular Partners AG (MOLN). It indicates that relevant data for business segments, regional revenue, and profit contribution has not yet been disclosed by the company. The only specific detail mentioned is "Switzerla
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 18 Jun 2026 09:39
- Source
- TradingKey
Molecular Partners AG (MOLN) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of the dividend and stock split history for Molecular Partners AG (MOLN). It notes that the company has not distributed any dividends over the past five years and has no recorded stock split data. The current stock price and market capitalization
- Tone
- Neutral 50/100
- Event
- Capital return
- Published
- 18 Jun 2026 06:39
- Source
- TradingKey
Molecular Partners AG (MOLN) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the major shareholders and institutional holdings of Molecular Partners AG (MOLN). It identifies Suvretta Capital Management, LLC, BVF Partners L.P., and SmartHarvest Portfolios, LLC as key shareholders and outlines their proportions. The report also provides
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Jun 2026 00:39
- Source
- TradingKey
Molecular Partners AG (MOLN) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Molecular Partners AG (MOLN), highlighting its current price momentum score of 6.49 within the Biotechnology & Medical Research industry. It identifies the stock trading between a resistance level of $4.29 and a support level of $3.60
- Tone
- Negative 40/100
- Event
- Market update
- Published
- 17 Jun 2026 10:11
- Source
- TradingKey
Molecular Partners AG (MOLN) Risk Assessment: Volatility, Financial Risk & Investment Risk
This article provides a risk assessment for Molecular Partners AG (MOLN), highlighting its current risk score of 2.80 within the Biotechnology & Medical Research industry and a beta value of 1.07. It details various risk metrics including volatility, maximum drawdown, and return-
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 17 Jun 2026 09:11
- Source
- TradingKey
Molecular Partners Holds Presentations at ASCO and SNMMI 2026 on DLL3-Targeting Radio-DARPin MP0712, Now Dosing Patients in Phase 1
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 30 May 2026 12:00
- Source
- GlobeNewswire
Molecular Partners AG to Present MP0712 Phase 1/2a Study Findings at 2026 ASCO and SNMMI Annual Meetings
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 30 May 2026 07:00
- Source
- Quiver Quantitative
Molecular Partners to Present at TD Cowen’s 7th Annual Oncology Innovation Summit
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 26 May 2026 20:00
- Source
- GlobeNewswire
There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 15 May 2026 07:00
- Source
- simplywall.st
Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 May 2026 07:00
- Source
- Market source
Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- simplywall.st
Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- Market source
Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Apr 2026 07:00
- Source
- Market source
Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 21 Apr 2026 07:00
- Source
- Market source
A Look Back at Biotechnology Stocks’ Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 29 Mar 2026 07:00
- Source
- TradingView
Molecular Partners and Orano Med Strengthen Agreement to Co-Develop 212Pb-Based Radio-DARPin Therapeutics
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 21 Oct 2024 07:00
- Source
- Stock Titan
MOLECULAR PARTNERS AG (MOLN) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Molecular Partners AG (MOLN)
- Tone
- Negative 34/100
- Event
- Regulatory and legal
- Published
- 01 Sep 2022 21:09
- Source
- TMX Newsfile
MOLECULAR PARTNERS (MOLN) Stock News & Updates
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 08 Jul 2021 05:00
- Source
- Stock Titan